Lake Street lowered the firm’s price target on Biodesix (BDSX) to $2 from $3 and keeps a Buy rating on the shares after the company reported Q1 revenue short of the firm’s estimate and consensus and reduced 2025 revenue guidance to $80M-$85M from $92M-$95M. Following the report, the firm reduced its price target to reflect multiple compression and near-term uncertainty surrounding the implementation of the new sales infrastructure.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDSX: